IXICO is a publicly funded company based in London, United Kingdom, founded in 2004 by Derek Hill, Daniel Rueckert, David Hawkes, and Jo Hajnal. It operates in the Biotechnology Research industry, specializing in neuroimaging and biomarker analytics for neurological disease research. IXICO has raised $5.2 million in funding, with Gresham House as the lead investor. The company has 79 employees and is listed on the AIM under the stock symbol IXI.
IXICO Corporate Details & Core Services
IXICO is a UK-based clinical research firm specializing in neuroimaging and digital biomarker analytics for biopharmaceutical companies conducting clinical trials into neurological diseases such as Alzheimer's and Huntington's.
An AI-enabled neuroimaging technology platform for precision medicine in neurological disease research.
What are the latest developments at IXICO?
Date
Type
Description
October, 2025
news
IXICO announced a trading update for the financial year ending 30 September 2025, anticipating revenues to be at least £6.3 million, ahead of expectations and representing a 9% increase on 2024 revenues.
What are IXICO's official legal and registration details?
Name
Description
Legal Name
IXICO plc
Cin number
GST number
Registration number
03131723
Who is in IXICO's executive leadership team?
Name
Designation
CEO
Bram Goorden
Chief Financial Officer
Grant Nash
Chief Scientific and Medical Officer
Robin Wolz
Where are IXICO's primary office locations?
City
Country
London
United Kingdom
What are the current business signals and market intelligence for IXICO?
Spending next 3 months
Technology development, Market expansion, Clinical trial support
Pain points
Data variability in clinical trials, Need for precise imaging biomarkers, Complexity in neuroimaging data analysis
Sales motion
Direct sales to biopharmaceutical companies, Partnerships with academic institutions, Collaborations with non-profits
